Latest News
OEHHA has provided a number of comments on the risk characterization methodology and conclusions on the draft RCD for Fenoxaprop Ethyl .
OEHHA has provided a number of comments on the risk characterization methodology and conclusions on the draft RCD for Molinate.
OEHHA has provided a number of comments on the risk characterization methodology and conclusions on the draft RCD for Mevinphos.
OEHHA has provided a number of comments on the risk characterization methodology and conclusions on the draft RCD for Hydrogen Cyanamide.
This final statement of reasons sets forth the reasons for the repeal of Section 12713 (Exposure to Foods, Drugs, Cosmetics, and Medical Devices) and the amendment to Section 12701 (General), and responds to the objections and recommendations submitted regarding these actions.
OEHHA has provided a number of comments on the risk characterization methodology and conclusions on the draft RCD for Cycloate.
OEHHA has provided a number of comments on the risk characterization methodology and conclusions on the draft RCD for Paclobutrazol.
OEHHA has provided a number of comments on the risk characterization methodology and conclusions on the draft RCD for Abamectin.
The purpose of this regulation is to provide "safe harbor" no significant risk levels for dichloromethane (methylene chloride), trichloroethylene, and vinyl chloride.
This regulation adopts "no significant risk" levels for Hexachlorodibenzodioxin (HCDD) of 0.0002 microgram per day and 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) of 0.000005 microgram per day.